泽璟制药：上半年亏损7280.35万元

Core Viewpoint - Zejing Pharmaceutical (688266) reported a significant increase in revenue for the first half of 2025, driven by the inclusion of its recombinant thrombin in the national medical insurance drug list, although it still faced a net loss [1] Financial Performance - The company achieved an operating revenue of 376 million yuan, representing a year-on-year growth of 56.07% [1] - The net profit attributable to the parent company was a loss of 72.8035 million yuan [1] Product Development - The sales of recombinant thrombin saw a notable increase after being officially included in the national medical insurance drug list during the reporting period [1]